account_id none on file
legal_name Ovid Therapeutics Inc.
ticker OVID
cik 1636651
domain ovidrx.com
linkedin_company_url https://www.linkedin.com/company/10062052/
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 9 executives 4 family 0
why_nownone on file
callsnone on file
filings
Other general and administrative expenses include costs associated with operating as a public company, travel expenses, conferences, professional fees for auditing, tax and legal services, and facility-related costs.
filing / Aug 13, 2026 / receipt
The increase in general and administrative expenses is primarily due to increased accounting and audit, legal, business development and other professional fees, as well as an increase in payroll and related expenses resulting from increased headcount between the three month periods as well as recognition of approximately $0.3 million of severance costs and sign-on bonuses in the three months ended June 30, 2026.
filing / Aug 13, 2026 / receipt
We may be required to take additional actions beyond cost reduction measures initiated to address our liquidity needs, including exploring other strategic options, reduce operating expenses or delaying, reducing the scope of, discontinuing or altering our research and development activities.
filing / Aug 13, 2026 / receipt
In September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,000 square feet of office space at Hudson Commons in New York, New York.
filing / Aug 13, 2026 / receipt
Severance expense 209 - 209 435 Gain from recovery of fraudulent funds transfer - - - 1,800 Depreciation and amortization 16 99 51 240 26 Table of Contents Item 2.
filing / Aug 13, 2026 / receipt
Other general and administrative expenses include costs associated with operating as a public company, travel expenses, conferences, professional fees for auditing, tax and legal services, and facility-related costs.
filing / May 12, 2026 / receipt
resulting from lower headcount between the three month periods as well as recognition of approximately $0.6 million of severance costs and sign-on bonuses in the three months ended March 31, 2025.
filing / May 12, 2026 / receipt
In September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,000 square feet of office space at Hudson Commons in New York, New York.
filing / May 12, 2026 / receipt
Severance expense - 435 Gain from recovery of fraudulent funds transfer - 1,800 Depreciation and amortization 35 141 24 Table of Contents Item 2.
filing / May 12, 2026 / receipt
executives
| Charles Carter | Chief Financial Officer | receipt | |
| Jeffrey Rona | Chief Business and Financial Officer | receipt | |
| Jeremy M. Levin | President | - | receipt |
| Robert Michael Poole | director | - | receipt |
familynone on file
upcoming
| 2026-11-11 | earnings call | scheduled | ir |
changes
| 2026-07-08 | Chief Financial Officer, appointed | sec_8k |
| 2021-08-11 | director, appointed | sec_8k |
| 2021-07-08 | President, appointed | sec_8k |
| 2021-06-04 | Chief Business and Financial Officer, appointed | sec_8k |
mcp_package_hint
slug ovid-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$